BridgeBio Pharma, Inc. (BBIO)
- Previous Close
24.98 - Open
24.85 - Bid 24.94 x 200
- Ask 25.00 x 200
- Day's Range
24.78 - 25.52 - 52 Week Range
12.75 - 44.32 - Volume
1,622,617 - Avg. Volume
1,714,083 - Market Cap (intraday)
4.602B - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-3.95 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
49.00
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
bridgebio.comRecent News: BBIO
Performance Overview: BBIO
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BBIO
Valuation Measures
Market Cap
4.61B
Enterprise Value
5.91B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
437.03
Price/Book (mrq)
--
Enterprise Value/Revenue
635.46
Enterprise Value/EBITDA
-10.45
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-64.07%
Return on Equity (ttm)
--
Revenue (ttm)
9.3M
Net Income Avi to Common (ttm)
-643.2M
Diluted EPS (ttm)
-3.95
Balance Sheet and Cash Flow
Total Cash (mrq)
434.88M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-249.07M
Research Analysis: BBIO
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: BBIO
Daily – Vickers Top Insider Picks for 03/29/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Buyers & Sellers for 02/22/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/19/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.